1.99
+0.09(+4.74%)
Currency In USD
| Previous Close | 1.9 |
| Open | 1.89 |
| Day High | 2.04 |
| Day Low | 1.89 |
| 52-Week High | 75 |
| 52-Week Low | 1.42 |
| Volume | 320,044 |
| Average Volume | 274,939 |
| Market Cap | 3.7M |
| PE | -0.16 |
| EPS | -12.38 |
| Moving Average 50 Days | 2.92 |
| Moving Average 200 Days | 10.74 |
| Change | 0.09 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $1.99 as of October 02, 2025 at a share price of $1.99. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $8.19 as of October 02, 2025 at a share price of $1.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
GlobeNewswire Inc.
Sep 26, 2025 12:00 PM GMT
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webin
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
GlobeNewswire Inc.
Aug 13, 2025 8:05 PM GMT
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stag
BioVie Inc. Announces Closing of $12 Million Public Offering
GlobeNewswire Inc.
Aug 11, 2025 8:05 PM GMT
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and